Evidence map›Paper›PMID 31323961›Full record

ArticleInternational journal of molecular sciences2019

Blockade of STAT3 Signaling Contributes to Anticancer Effect of 5-Acetyloxy-6,7,8,4'-Tetra-Methoxyflavone, a Tangeretin Derivative, on Human Glioblastoma Multiforme Cells.

Yen-Po Cheng, Shiming Li, Wan-Ling Chuang, Chia-Hsuan Li, Guan-Jun Chen, Ching-Chin Chang, Chi-Hung R Or, Ping-Yi Lin, Chia-Che Chang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Yen-Po ChengDivision of Neurosurgery, Department of Surgery, Yuanlin Changhua Christian Hospital, Changhua 50006, Taiwan.
Shiming LiHubei Key Laboratory for Processing and Application of Catalytic Materials, Huanggang Normal University, Huanggang 438000, China.
Wan-Ling ChuangTransplant Medicine & Surgery Research Center, Changhua Christian Hospital, Changhua 50006, Taiwan.ORCID 0000-0001-8815-3834
Chia-Hsuan LiInstitute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan.
Guan-Jun ChenInstitute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan.
Ching-Chin ChangInstitute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan.
Chi-Hung R OrDepartment of Anesthesiology, Tungs' Taichung MetroHarbor Hospital, Taichung 43503, Taiwan.
Ping-Yi LinTransplant Medicine & Surgery Research Center, Changhua Christian Hospital, Changhua 50006, Taiwan. 69221@cch.org.tw.
Chia-Che ChangInstitute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan. chia_che@dragon.nchu.edu.tw.ORCID 0000-0003-3509-3713
Asia University · TWNational Chung Hsing University · TWChanghua Christian Hospital · TWChina Medical University · TWHuanggang Normal University · CN

Funding

The iEGG and Animal Biotechnology Center from The Feature Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan no grant number applied
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor prognosis, largely due to resistance to current radiotherapy and Temozolomide chemotherapy. The constitutive activation of Signal Transducer and Activator of Transcription 3 (STAT3) is evidenced as a pivotal driver of GBM pathogenesis and therapy resistance, and hence, is a promising GBM drug target. 5-acetyloxy-6,7,8,4'-tetramethoxyflavone (5-AcTMF) is an acetylated derivative of Tangeretin which is known to exert anticancer effects on breast, colon, lung, and multiple myeloma; however, its effect on GBM remains elusive. Herein, we reported that 5-AcTMF suppressed the viability and clonogenicity along with inducing apoptosis in multiple human GBM cell lines. Mechanistic analyses further revealed that 5-AcTMF lowered the levels of Tyrosine 705-phosphorylated STAT3 (p-STAT3), a canonical marker of STAT3 activation, but also dampened p-STAT3 upregulation elicited by Interleukin-6. Notably, ectopic expression of dominant-active STAT3 impeded 5-AcTMF-induced suppression of viability and clonogenicity plus apoptosis induction in GBM cells, confirming the prerequisite of STAT3 blockage for the inhibitory action of 5-AcTMF on GBM cell survival and growth. Additionally, 5-AcTMF impaired the activation of STAT3 upstream kinase JAK2 but also downregulated antiapoptotic BCL-2 and BCL-xL in a STAT3-dependent manner. Moreover, the overexpression of either BCL-2 or BCL-xL abrogated 5-AcTMF-mediated viability reduction and apoptosis induction in GBM cells. Collectively, we, for the first time, revealed the anticancer effect of 5-AcTMF on GBM cells, which was executed via thwarting the JAK2-STAT3-BCL-2/BCL-xL signaling axis. Our findings further implicate the therapeutic potential of 5-AcTMF for GBM treatment.

Indexed as

Antineoplastic AgentsApoptosisbcl-X ProteinCell LineCell Line, TumorCell SurvivalFlavonesGlioblastomaHumansInterleukin-6Open Reading FramesSTAT3 Transcription FactorAntineoplastic Agentsbcl-X ProteinflavoneFlavonesInterleukin-6STAT3 Transcription Factortangeretin5-acetyloxy-6,7,8,4′-tetramethoxyflavoneapoptosisBCL-2BCL-xLglioblastoma multiformepolymethoxyflavoneSTAT3tangeretin

Identifiers

PMID31323961
PMCPMC6651290
OpenAlexW2962551393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.